TORONTO--(BUSINESS WIRE)--Biovail Corporation (NYSE:BVF)(TSX:BVF) today announced that the Therapeutic Products Directorate (TPD) Canada has issued a Notice of Compliance (NOC) for 100mg, 200mg and 300mg tablet strengths of Ralivia™, the Company’s once-daily, extended-release formulation of tramadol hydrochloride indicated for the management of pain of moderate severity in patients who require continuous treatment for several days or more.
